Editors' Desk

1. The Compounded Risk Of Early-Stage Biopharma Licensing Deals 6/25/2020

   A new paper illustrating big pharma’s tendency to backfill phase three failures by rushing into new licensing deals underscores a risk to emerging biotechs.

2. Mechanistic Action: Genesis Of A Biologics Pipeline? 6/17/2020

   Cue Biopharma President & CSO Anish Suri, Ph.D. tells us why a partnership with The University Of Oxford to visualize the mechanistic action of molecules at the immunological synapse could provide insights that guide future drug discovery and development strategy.

3. Precision Medicine In Practice 6/16/2020

   Precision medicine is bringing biopharma closer to the patient. The Christ Hospital Health Network Director Of Precision Medicine Dr. Burns Blaxall discusses why clinical-level practitioners are the key link between biopharmas and patients, and how AI is helping to define the practice.

4. Securing Biotech Funding When Economies Get Wild 6/12/2020

   There’s disruption on the startup biotech money trail. Navigating it requires a pliable strategy. Here, multi-time founder and investor Bert Liang shares insight on raising funds during volatile times. 

5. A New Cost Paradigm For CAR Cell Therapies? 6/12/2020

   Hear from Acepodia CEO Sonny Hsiao about his company's claims that its proprietary approach to conjugating novel natural killer cells could reduce the cost of cellular therapeutics.

6. Is Biopharma’s Response To Coronavirus Off The Mark? 3/4/2020

   As biopharmas aplenty race to develop a vaccine, CureLab’s Alex Shneider says an incorrect approach risks turning the currently insignificant coronavirus threat into a deadly pandemic. He suggests that we instead focus on the development of adjuvants and immunostimulants to protect the elderly.

7. New U.S And Canadian Facilities Boosting Biologics Capacity 4/13/2018

   Biopharma executives have warned they need more biologics development and manufacturing capacities, particularly in North America. They haven’t been howling at the moon. Four announcements – within two days of each other – offer a sign of relief. And Amgen has provided Outsourced Pharma with its first public estimate of costs for one of those facilities.

8. A Glimpse Into Thailand’s Ongoing Life Sciences Transformation 5/18/2017

   During my visit to Thailand, I was privy, not only to the particularly innovative research goals being pursued, but also to a number of challenges the country has recognized and hopes to address within the next few years to encourage a stronger, more diverse industry.

9. What Thailand Revealed About U.S. Pharma R&D 5/16/2017

   A few weeks ago, I was invited by the Thailand Board of Investment to attend a media trip to learn about the country’s budding life sciences industry. Entering Thailand, a country in which the government is pushing more investment and education in the sciences, was even more striking and meaningful to me given the current scientific climate in the U.S.

10. Top 5 Biosimilar Developments Of 2016 12/29/2016

    In the spirit of this list-making season, I compiled what I thought were the five most important biosimilar-related triumphs in the past year. Many of these events were widely covered by the media and will play an influential role in how the biosimilar industry unfolds through 2017 and beyond.